B. Metzler seel. Sohn & Co. AG Lowers Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

B. Metzler seel. Sohn & Co. AG lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 30.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 23,096 shares of the biopharmaceutical company’s stock after selling 10,087 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Halozyme Therapeutics were worth $1,104,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HALO. Arrowstreet Capital Limited Partnership raised its stake in Halozyme Therapeutics by 141.3% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock valued at $47,470,000 after purchasing an additional 581,475 shares during the period. Pictet Asset Management Holding SA grew its holdings in Halozyme Therapeutics by 11.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 18,900 shares of the biopharmaceutical company’s stock valued at $904,000 after buying an additional 1,946 shares in the last quarter. New Age Alpha Advisors LLC bought a new stake in Halozyme Therapeutics in the 4th quarter worth approximately $1,351,000. Norges Bank bought a new stake in Halozyme Therapeutics in the fourth quarter worth $60,054,000. Finally, EFG Asset Management North America Corp. raised its stake in Halozyme Therapeutics by 18.3% during the fourth quarter. EFG Asset Management North America Corp. now owns 128,294 shares of the biopharmaceutical company’s stock valued at $6,133,000 after purchasing an additional 19,881 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Benchmark reiterated a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company lowered their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $62.78.

Halozyme Therapeutics Trading Down 1.7 %

Shares of NASDAQ HALO opened at $61.92 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $66.00. The firm has a market cap of $7.65 billion, a PE ratio of 18.05, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The business has a fifty day simple moving average of $59.74 and a two-hundred day simple moving average of $54.95. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company’s stock, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,200 shares of company stock worth $1,786,668. 2.90% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.